【Product Overview】 We are a premier global supplier of CJC-1295 No DAC, chemically identified as Modified GRF 1-29. This tetrasubstituted analogue of Growth Hormone-Releasing Hormone (GHRH) is one of the most sought-after peptides in metabolic research. Unlike the "DAC" version which provides continuous release, CJC-1295 No DAC is engineered to mimic the body's natural pulsatile GH secretion. We provide high-purity, research-grade material ideal for studies requiring physiological hormone spikes and synergistic protocols.

【Key Advantages】

Pulsatile Mechanism: CJC-1295 No DAC has a biological half-life of approximately 30 minutes. This allows researchers to stimulate natural, pulse-like growth hormone release, avoiding the "GH bleed" or pituitary desensitization often associated with long-acting continuous agonists.

Enhanced Stability: Compared to native Sermorelin (GRF 1-29), our product features four specific amino acid substitutions (Tetrasubstituted) that protect it from enzymatic cleavage by DPP-IV. This results in significantly improved bioavailability and potency.

Synergistic Potential: This peptide is the industry standard for "Peptide Stacking" research. It is most commonly purchased alongside GHRPs (like Ipamorelin or GHRP-2) to investigate synergistic effects (1+1>2) on GH output.

High Purity Guarantee: We deliver ≥99.0% purity (HPLC). We strictly control for truncated sequences and deletion by-products, ensuring you receive a full-length, active peptide.

【Logistics & Service】

Global Export: We are experienced in shipping GHRH analogues to the US, EU, and Asia. We provide full HS Code support and customs documentation.

Flexible Inventory: Available in standard 2mg and 5mg vials, as well as bulk powder (grams) for commercial formulation or compounding requirements.

Regulatory Disclaimer: This product is supplied as a Chemical Reference Standard or API Intermediate for laboratory research (R&D) and further manufacturing use only. It is NOT intended for direct human therapeutic use, clinical injection, or patient administration without regulatory approval.